Clinical trials: Malignant Melanoma
Malignant Melanoma, Liver Metastases
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
This study is the first to explore the efficacy and safety of recombinant human adenovirus type 5 injection combined with PD-1 monoclonal antibody and nab-paclitaxel in the treatment of patients with liver metastases of melanoma…
- Trial name
- NCT05664139
- Testing
- Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Skin Cancer, Non-Melanoma
Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk
The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in…
- Trial name
- NCT03040492
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Melanoma Stage III, Melanoma Stage IV
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
- Trial name
- NCT04741997
- Testing
- Encorafenib Pill, Binimetinib Pill, Nivolumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia, Melanoma
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment.
- Conditions
- Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer
- Trial name
- CANSI (NCT05212103)
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Turku University Hospital
Melanoma
NIR-Guided Sentinel Lymph Node Mapping in Melanoma
This study will try to define an appropriate dose of the investigational drug indocyanine green (ICG) in combination with near infrared (NIR) imaging to use for future studies.
- Trial name
- NCT01121718
- Testing
- ICG Intervention
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Metastatic Melanoma, Liver Metastases
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to…
- Trial name
- NCT07281924
- Testing
- Nivolumab and Relatlimab, Melphalan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Melanoma
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,
- Trial name
- NCT02872259
- Testing
- BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab
- Where
- 5 sites in Norway
- Volunteers
- 74 people
- Sponsor
- Haukeland University Hospital
Melanoma (Skin)
Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Over 5 million new cases of skin cancer are diagnosed in the United States each year, more than all other cancers combined. Most of these cases are caused by excess exposure to ultraviolet radiation from the sun and artificial…
- Trial name
- NCT03927742
- Testing
- Shade + app with messaging, Shape + app without messaging
- Where
- United States
- Volunteers
- 368 people
- Sponsor
- University of Minnesota
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases…
- Trial name
- HAITILS (NCT04812470)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Vastra Gotaland Region
BRAF Mutant Metastatic Melanoma
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant…
- Trial name
- NCT01512251
- Testing
- BKM120 Combined with Vemurafenib (PLX4032)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
Non-melanoma Skin Cancer
A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-Melanoma Skin Cancer (NMSC) is the most commonly occurring type of skin cancer, and predominantly comprises (98%) Basal Cell Carcinomas (BCC) and Squamous Cell Carcinomas (SCC).
- Trial name
- NCT03693937
- Testing
- SRT-100
- Where
- United States
- Volunteers
- 776 people
- Sponsor
- Sensus Healthcare
Non-melanoma Skin Cancer
Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer
Radiotherapy is a treatment considered standard for non melanoma skin cancer. This institution uses schemes of 4 to 6 weeks of treatment.
- Trial name
- NCT02080962
- Testing
- 30 Gy in 5 fractions, 40 Gy in 10 fractions
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Barretos Cancer Hospital
Immuno-monitoring
Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy
This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived…
- Trial name
- ImmunoPAX (NCT02332642)
- Testing
- Immuno-monitoring
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Universitätsmedizin Mannheim
Malignant Melanoma
Vaccine Therapy for Patients With Stage IV Melanoma
This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed.
- Trial name
- NCT00052156
- Testing
- CancerVax vaccine (CANVAXIN)
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 670 people
- Sponsor
- CancerVax Corporation
Melanoma Advanced
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
- Trial name
- NCT07445022
- Testing
- tunlametinib
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Fudan University
Breast Cancer, Melanoma
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) for Navidea's Lymphoseek for use in intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the…
- Trial name
- NCT00671918
- Testing
- Lymphoseek
- Where
- 15 sites in United States, Israel
- Volunteers
- 186 people
- Sponsor
- Navidea Biopharmaceuticals
Solid Tumor, Adult, Solid Tumor
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
- Conditions
- Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer
- Trial name
- NCT06398418
- Testing
- R-5780
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Rise Therapeutics LLC
Malignant Melanoma
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma.
- Trial name
- NCT01006980
- Testing
- Vemurafenib, Dacarbazine
- Where
- 111 sites in United States, Australia and 10 more
- Volunteers
- 675 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.